Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  SANOFI    SAN   FR0000120578

SANOFI (SAN)

2386
Real-time Quote. Real-time Tradegate - 07/28 04:02:31 pm
76.184 EUR   +0.27%
5h agoDJOfficials Visit Microsoft's China Offices -- Update
4d ago SANOFI : Merial Assigned Patent
4d ago SANOFI INDIA : Q2 NET INCREASES 12.3% TO Rs57.5 CRORE
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 

SANOFI : EMA Recommends Approval Of Sanofi Pediatric Vaccine Hexyon/Hexacima 6-in-1

02/22/2013 | 07:58am US/Eastern
Recommend:
0

PARIS--The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) recommended market approval for Sanofi Pasteur's 6-in-1 pediatric vaccine, French drugs giant Sanofi (>> SANOFI) said Friday.

MAIN FACTS:

- Hexyon/Hexacima is the only fully liquid, ready-to-use, 6-in-1 vaccine to protect infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.

- The new vaccine will be commercialized under the brand name Hexyon in Western European countries by Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur, and under the brand name Hexacima in Eastern European countries by Sanofi Pasteur.

- The vaccine "reduces the number of vaccination visits for infants and it is more convenient for parents to complete the recommended vaccination schedule and thus better protect their children against six major childhood diseases," said Olivier Charmeil, President and CEO of Sanofi Pasteur.

-Hexyon/Hexacima would be indicated for primary and booster vaccination of infants from six weeks of age in accordance with official recommendations.

- The CHMP positive opinion is supported by results of multi-center clinical studies involving approximately 5,000 infants; phase III clinical studies comparing Hexyon/Hexacima to licensed combination vaccines demonstrated that HexyonTM/HexacimaTM is safe and induces a robust immune response against all six targeted diseases.

-Write to Mimosa Spencer at mimosa.spencer@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
Recommend :
0
React to this article
Latest news on SANOFI
5h agoDJOfficials Visit Microsoft's China Offices -- Update
4d ago SANOFI : Merial Assigned Patent
4d ago SANOFI INDIA : Q2 NET INCREASES 12.3% TO Rs57.5 CRORE
5d ago GENZYME : Patent Issued for Synthesis of UDP-Glucose: N-Acylsphingosine Glucosyl..
5d ago GENZYME : Exact Sciences Reports Second-Quarter 2014 Financial Results
5d ago GlycoMimetics Introduces Mark A. Goldberg, M.D. to Board of Directors
6d ago EXCLUSIVE - INDIA'S LUPIN, U.S. FIRM : sources
6d ago SANOFI : Information concerning the total number of voting rights and shares
6d ago India's Lupin, U.S. firms weigh bids for GSK's mature drugs -sources
6d ago SANOFI : Pasteur : Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-..
Advertisement
Chart
Duration : Period :
SANOFI Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Income Statement Evolution
SANOFI : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF